The 2016 National Pathology Technology Annual Conference Successfully Concludes in Fuzhou
The 2016 National Pathology Technology Conference, organized by the Chinese Medical Association and the Pathology Technology Group of the Chinese Society of Pathology, and hosted by the Pathology Technology Group of the Fujian Provincial Medical Association Pathology Branch, was successfully held in Fuzhou, Fujian Province from September 16 to 18, 2016. The conference agenda was compact and substantial. As a local enterprise, Maixin, together with over 500 pathology colleagues from frontline pathology technicians, research institutes, and industry across the country, witnessed this grand event. We also shared our latest technological advancements and achievements with the attending experts and colleagues.
The conference focused on special lectures and discussions regarding the standardization of pathological tissue specimen fixation, sampling, tissue dehydration, the standardization of immunohistochemical technology, the development and application of new molecular biology technologies, quality control in pathology technology, and the management of informatization and pathology technology work. The content was substantial, grounded in the practice of pathology work, yet innovative, greatly enhancing the academic atmosphere of national pathology technology.
Maixin Company has long focused on the development of pathology technology. At this technical annual meeting, General Manager Wang Xiaoya delivered a speech titled ‘Maixin Promotes Immunohistochemistry, Immunohistochemistry Promotes Pathology Progress’ to the attending pathology technology colleagues. She reported on Maixin’s current main research progress, especially in antibody development and automated instrument development, demonstrating the determination to ‘break monopolies and enable Chinese pathologists to use domestic clones and equipment.’ At the same time, she briefly elaborated on the current national regulatory policies for immunohistochemical products, hoping to work with the broader pathology community to face the current situation and issues of unlicensed use of IVD reagents and actively seek solutions.
At this conference, Maixin Company’s booth was also an unmissable highlight. Through product displays, video presentations, and on-site Q&A sessions, Maixin attracted the attention of many attendees, becoming a focal point of the event. In particular, the newly launched fully automated immunohistochemical staining instrument, Lumatas-Titan, made its debut at a major national conference for the first time, attracting numerous conference representatives to stop and inquire. The instrument’s high throughput and stable performance received high praise from the participants.
This National Pathology Technology Annual Meeting served as an excellent communication platform for pathology technology colleagues and a platform for Chinese pathology technology to learn from and draw upon advanced pathology techniques, enhancing communication and understanding. Through this conference, Maixin Company gained a deeper understanding of current new technologies, directions, and achievements in pathology, providing reference for future new product and technology development and improvement. At the same time, it strengthened connections with pathology peers, allowing more pathologists to gradually understand and become familiar with the Maixin brand.